The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation

Jamie Drossaerts^{a, b} Kevin L.J. Rademakers^{a, b} Sajjad M. Rahnema^{i a, b}
Tom Marcelissen^a Philip Van Kerrebroeck^{a, b} Gommert van Koevinge^{a–c}

^aDepartment of Urology, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands; ^bSchool of Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands; ^cPelvic Care Centre Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands

Keywords

Sacral neuromodulation · Urodynamic study · Ambulatory monitoring · Overactive bladder · Non-obstructive urinary retention · Underactive bladder · Urinary bladder · Overactive · Urinary retention

Abstract

Objectives: To assess the improvement of symptoms by sacral neuromodulation (SNM) in an objective way by carrying out an ambulatory urodynamic study (ambulatory-UDS). Until now, successful treatment has been defined as a $\geq 50\%$ improvement recorded on voiding diaries. Voiding diaries are a patient reported outcome tool. A tool with less bias is desired to evaluate the treatment results before an expensive permanent system is implanted. **Methods:** Between 2002 and 2015, a total of 334 patients with lower urinary tract symptoms were included consecutively in an ambulatory-UDS database. From this database, a subgroup of patients was selected which underwent SNM. **Results:** In 51 patients, an ambulatory-UDS was performed both at baseline and during the SNM test period. A positive treatment outcome after test stimulation based on the patients' voiding diary, correlated ($p < 0.0001$) with an improvement on ambulatory-

UDS. Twenty-six of the 30 patients, who have showed improvement of more than 50% on voiding diary parameters and who had subjective improvement of their symptoms, showed an early improvement on ambulatory-UDS. **Conclusions:** Ambulatory-UDS can be used in clinical decision making, as it is associated with voiding diary improvement during the SNM test period. Using ambulatory-UDS to confirm success could in the future justify the shortening of the test period.

© 2019 The Author(s)
Published by S. Karger AG, Basel

Introduction

In this study, we investigated the value of an ambulatory urodynamic study (ambulatory-UDS) for the evaluation of treatment effect during the test evaluation period in sacral neuromodulation (SNM). Since the 1990s SNM is a recommended treatment in patients with overactive bladder syndrome (OAB) or non-obstructive uri-

K.L.J.R. and S.R. contributed equally to the manuscript.

nary retention (NOR), for cases where conservative treatments failed or adverse events prevented therapy continuation [1]. As this treatment is invasive and expensive, a standard testing period is applied before embarking on a permanent implantation. Often eligible patients are affected by NOR or OAB for several years or even decades [2]. In general, treatment success of SNM is assessed by voiding diaries, subjective patient improvement, quality of life scores and symptom score questionnaires [1]. The final clinical decision concerning treatment success is dependent upon voiding diaries in most treatment centres and this is in line with the recommendation by most experts in the field. SNM success is therein defined as a reduction of one or more voiding symptoms with $\geq 50\%$, compared to the baseline situation. Although voiding diaries have been proven to be a reliable tool, they remain patient reported and hence will introduce inevitable bias. It is preferable to assess improvement of symptoms in a standardised and more objective (unambiguous) way.

In the past, an association between an improvement on a cystometrogram and the SNM treatment outcome was suggested. A significant correlation was found between improvement in symptoms and changed conventional-UDS recording in patients with NOR [3–5]. Similar significant correlations in OAB patients treated with SNM have been reported [6–8]. Unfortunately to date no comprehensive and objective assessment method has been developed for treatment evaluation. One of the reasons for this might be the situational sensitivities of conventional urodynamics that prevents a detection of representative changes [9]. The use of ambulatory-UDS may be a helpful tool to objectively assess the improvement of symptoms and overcome the hurdles of a conventional-UDS.

An ambulatory-UDS is defined as a functional assessment of the lower urinary tract: monitoring storage and voiding, utilising natural filling while the subject's every day activities are reproduced [10]. The first to establish ambulatory-UDS was Comarr [11]. Since its development and a more widely use of ambulatory-UDS in the 1990s [12], a reasonable number of studies have been performed to assess the applicability of ambulatory-UDS in clinical practice. Ambulatory-UDS was standardised in 2,000 [10], but is yet to be validated clinically.

In this paper, treatment-induced changes on ambulatory urodynamic studies in patients treated with SNM are reviewed. The aim of this study is to explore to what extent the improvement in ambulatory UDS recordings can be used in the clinical decision making.

Methods

Patient Selection

From December 2002 until April 2015, a total of 334 patients with lower urinary tract symptoms were included in a consecutive ambulatory-UDS database. From this database, a subgroup of patients was selected, who underwent ambulatory urodynamic monitoring prior to and during the test period for SNM. Urodynamic results were related to treatment evaluation. Clinical informed consent was obtained from all patients for the additional ambulatory-UDS. The approval of the Medical Ethical Committee of Maastricht University Centre was obtained.

Urodynamic Studies

All urodynamic measurements were performed with use of Medical Measurements Systems (MMS B.V., Enschede, the Netherlands) equipment and according to the standardisation report of the ICS [10, 13]. An initial ambulatory-UDS was conducted in all following cases: (1) low quality conventional-UDS (2) assumed OAB without detrusor overactivity (DO) on conventional-UDS (3) incontinence with unclear primary origin or (4) suspected bladder acontractility and (5) enuresis nocturna. When an ambulatory-UDS had been performed to clarify the diagnosis and this patient underwent subsequent SNM treatment, a second ambulatory-UDS was used to compare to baseline to possibly confirm either success or failure during the test period.

The quality of all ambulatory-UDS recordings was ascertained and the full results were interpreted by an urologist specialised in urodynamics and a urology resident experienced in evaluating urodynamic measurements. Both were blinded to the SNM outcome. Standard definitions were adhered to when judging the measurements.

Any phasic contraction during the filling phase with rise and fall in detrusor pressure is diagnostic of DO. The ICS definition does not specify a minimum change in detrusor pressure, although waves of amplitude less than 5 centimetre H₂O are difficult to detect. Bladder acontractility was defined as a filling and voiding phase without detrusor pressure rise. Hypocontractility was identified as a low detrusor pressure (less than 10 cm H₂O) during the voiding phase, relative to the degree of obstruction, not resulting in (efficient) micturition. In case of a conventional-UDS, the hypocontractility definition is elaborated with a peak flow rate (Q_{max}) of less than 10 mL/s, voided volume should be greater than 100 mL and residual urine volume greater than 150 mL [14]. For ambulatory-UDS standardised limits have not yet been established [15]. In Figure 1, an example of an ambulatory-UDS work place set up is shown.

Sacral Neuromodulation Treatment

SNM treatment success was defined as a reduction of one or more micturition symptoms to $\geq 50\%$, compared to baseline, determined by comparing voiding diaries. An SNM test period using the tined lead procedure covered 4 weeks. Every included patient served as their own control.

Statistical Analysis

Descriptive and comparative statistics were calculated with the use of SPSS, IBM corporation, version 22. The median and 25–75 percentile interquartile range were described. Pearson's chi-square test, Spearman's correlation, the positive and negative predictive value, sensitivity and specificity were calculated.

Fig. 1. Ambulatory urodynamic study set-up. **a** The luna wireless module for registration of events during the ambulatory-UDS. **b** Solar measurement system. **c** A patient equipped with measurement catheters and the Luna mobile device. **d** An example of one part of ambulatory-UDS recording.

Results

In 51 patients (32 women and 19 men), an ambulatory-UDS was performed at baseline and during the SNM test period. The mean age was 48.7 (SD 12.1); men were 52.1 (SD 12.3) and women were 46.6 (SD 11.7). Age was not statistically different between men and women (t test, $p = 0.893$). Most patients presented at the outpatient clinic with voiding LUTS, 37 of those had NOR, of which 17 were experiencing complete urinary retention and 20 were able to void more or less spontaneously but were still in need of catheterisation multiple times a day. An additional 10 patients had OAB complaints, 9 out of 10 were affected by OAB with urgency incontinence; one patient was continent. The remaining 4 patients presented with a combination of voiding

and storage LUTS. In these patients, no neurogenic conditions could be objectified. Out of the total group of 51 patients, 30 (59%) showed an improvement of $\geq 50\%$ on voiding diary parameters and reported subjective improvement of symptoms. These 30 patients received a definitive SNM implant. In the remaining 21 patients, the stimulating electrode was removed at the end of the test period, as no symptom improvement occurred (see Table 1). A neuromodulator was implanted in 80% (8/10) of the OAB group, 54% (20/37) of the NOR group and 50% (2/4) of the patients with combined symptoms.

A positive treatment outcome after test stimulation based on voiding diaries, correlated ($p < 0.0001$) well with an improvement on ambulatory-UDS (Table 2). Ambulatory-UDS duration was on average 6 h. The differences

Table 1. Ambulatory measurements from the baseline and testing period recordings in the unsuccessful patients

Averages ↓	Ambulatory-UDS data					
	baseline – NOR	testing period NOR failure	difference, %	baseline – OAB	testing period OAB failure	difference, %
Amount of fluid intake, mL	1,491	1,610	+7.4	842	978	+14
Amount of total diuresis, mL	914	1,056	+13.4	623	657	–5.2
Min voiding volume/void, mL	45	32	–40.6	25	40	+37.5
Max voiding volume/void, mL	350	300	–17	300	300	0
Max volume by catheterisation, mL	750	750	0	na	na	na
Frequency of voids	2.6	2.4	–17*	4.4	4.8	–64*
Contraction amplitude	20	20	0	82	71	–34.1*
Leakage frequency	0.3	0	–100	5	6	+3.3*
Amount of leakage, mL	9	0	–100	74	89	+4.4*

* Corrected for diuresis volume during the UDS.

Important remarks: passive drainage (catheterisation) during ambulatory-UDS is less convenient than normal self catheterisation, leading in some baseline NOR patients to a residual urine after the ending the recording of up to 500 mL's. Leakage was calculated from grams to estimate milliliters.

na, not applicable; UDS, urodynamic study; NOR, non-obstructive urinary retention; OAB, overactive bladder syndrome.

Table 2. Ambulatory-UDS outcome in SNM treatment 2 × 2 contingency table

SNM treatment*	Ambulatory-UDS outcome		Total	Calculations
	improved	unchanged		
Successful	26	4	30	PPV = 0.83
Failed	1	20	21	NPV = 0.95
Total	27	24	51	
	Sensitivity = 0.96			
		Specificity = 0.83		
Pearson's chi-square test		$X^2 = 40.7$; df = 1; $p < 0.0001$		
Spearman's correlation (rho)		$\rho = 0.81$; $p < 0.0001$		

* Success or failure of SNM treatment is based on the combination $\geq 50\%$ improvement in voiding parameters on voiding diaries and the subjective improvement reported by patients.

PPV, positive predictive value; NPV, negative predictive value; UDS, urodynamic study; SNM, sacral neuromodulation.

in measurements from the recordings for the successful patients are summarized in Table 3. Of the 30 implanted patients, 26 (87%) also showed improvement on ambulatory-UDS. Of all patients who had an unchanged recording, 83% (20/24) failed the test period and were not submitted to permanent implantation. One patient with improvement on ambulatory-UDS during the test period, presented with an acontractile bladder at baseline and the subsequent emergence of some micturition contractions during treatment. However, this patient did not report clinically relevant improvement on voiding diaries. Another patient showed $>50\%$ improvement in the degree and frequency of incontinence episodes, but despite this fact, the patient was not satisfied (enough) with the treat-

ment results. In this patient, improvement during ambulatory-UDS was consistent with improvement in the voiding diaries.

In 2 of the 4 patients with an unchanged ambulatory-UDS recording, the treatment effect was not reached at the time of the UDS. It was in fact unknown when exactly the treatment effect could be expected, therefore, and for reasons of hospital logistics, the ambulatory-UDS during the SNM test period was scheduled in advance. However, at a later time point, still within the 4 weeks test stimulation period, treatment was proven effective after all and these patients received a definitive implant. In these cases, unfortunately, the ambulatory-UDS was not repeated.

Table 3. Ambulatory measurements from the baseline and testing period recordings in the successful patients

Averages	Ambulatory-UDS data					
	baseline – NOR	testing period NOR success	difference, %	baseline – OAB	testing period OAB success	difference, %
Amount of fluid intake, mL	1,491	1,237	17	842	1,122	+33.3
Amount of total diuresis, mL	914	784	14.2	623	816	+31
Min voiding volume/void, mL	45	50	+11	25	150	+600
Max voiding volume/void, mL	350	780	+1,229	300	450	+150
Max volume by catheterisation, mL	750	150	80	na	na	na
Frequency of voids	2.6	3.1	7*	4.4	3.6	–38.6*
Contraction amplitude	20	35	+75	82	40	–63.4*
Leakage frequency	0.3	0	100	5	1	–85.0*
Amount of leakage, mL	9	na	100	74	22	–77.7*

* Corrected for diuresis volume during the UDS.

Important remarks: passive drainage (catheterisation) during ambulatory-UDS is less convenient than normal self catheterisation, leading in some baseline NOR patients to a residual urine after the ending the recording of up to 500 mL's. Leakage was calculated from grams to estimate milliliters.

na, not applicable; UDS, urodynamic study; NOR, non-obstructive urinary retention; OAB, overactive bladder syndrome.

Long-Term Outcome

Patient follow-up was on average 3.2 years (SD 3.8). The 1-year outcome for all 30 implanted patients was favourable. In the 26 patients who displayed improvement on ambulatory-UDS, no decrease in effect was noted during follow-up. Of the 4 implanted patients who did not show improvement on ambulatory-UDS, 2 showed a decrease in effect (but still >50% improvement) and 2 maintained the same treatment effect at 1-year follow-up.

Discussion

Up and until now, voiding diaries have been used as a gold standard for the assessment of SNM test period treatment outcome. Voiding diaries can be biased due to several reasons. The diaries can be filled out incorrectly or seem to show an improvement at a quick glance, but after correction, for example, for total fluid intake of the patient, will not show any sustained improvement. This study investigated whether in patients undergoing SNM the performance of an ambulatory-UDS could lead to an objective confirmation of success or failure of the treatment. Pressure-flow studies record and measure events real-time; however, they only capture symptoms during one particular and limited time frame. In the ambulatory setting, the study is performed during a longer period of time and with natural filling of the bladder and could

therefore have a higher chance of depicting patients' symptoms compared to a conventional-UDS. Several studies have proven that, in general, voiding diaries recorded by patients are highly accurate, reproducible and more accurate than just the patient's recollection [16, 17]. However, other studies have shown that in women with urinary incontinence, the correlation between their history and voiding frequency recorded in voiding diaries appeared to be weak [18]. A final statement on the exact value of voiding diaries is yet to be made.

Some have suggested that pressure-flow cystometry mainly gives a qualitative measure of urgency, whereas the voiding diary offers objective and reliable quantitative information of the symptoms and thus supplements the cystometric evaluation. These studies concluded that combining history and voiding diaries was too unreliable and urodynamic testing should not be omitted. Adding data extracted from voiding diaries with other examinations (e.g., voiding diaries, validated symptom score questionnaire, urodynamic studies) may lead to a more adequate diagnosis and consequently, a better treatment response [19–22].

The severity of symptoms as recorded on voiding diaries has no association with the presence of DO [23]. In patients with storage dysfunction, regardless of the presence of DO, additional ambulatory-UDS does not seem to contribute to a better prediction of the success of SNM in the future [15]. In addition, the success of the treatment of idiopathic OAB with onabotulinumtoxinA blad-

der injections does not appear to be related to the finding of pretreatment DO either [24]. However, DO could be of importance in terms of its effect prediction of other treatments.

The ICS urodynamics committee recommends the use of ambulatory-UDS as a second line diagnostic in specific cases [25]. Our study shows that objective improvement on ambulatory-UDS is associated with the standard evaluation parameters of subjective treatment success and the more objective voiding diary parameters. This shows that the use of ambulatory-UDS are, at least, not inferior to the use of voiding diaries. Furthermore, ambulatory-UDS may help to perform a more objective evaluation of the test stimulation, especially in doubtful cases. Assessment with ambulatory urodynamics may accelerate the decision making process, when we compare this method with more time-consuming voiding diaries. The current standard test period for SNM constitutes 4 weeks; in current study results, we seem to see an earlier onset of effect in changed ambulatory-UDS recordings, than the later moment the symptom improvement becomes obvious. We thus speculate to shorten the test period substantially (± 2 weeks), but this should be supported by research developed to investigate this exact statement.

What currently complicates the decision-making process even more is that the exact cut-off value of voiding diary improvement to be used is still a topic of debate. Most experts in the field adhere to the $\geq 50\%$ improvement, but some have advocated for a $\geq 70\%$ improvement as a significant effect [26]. Others mention the success and cure rates separately, denominating on the one hand the group of patients with 50% improvement and the other hand the group, which have no symptoms at all after treatment by SNM [27]. It should be noted that current research adhering to the cut-off value of $\geq 50\%$ improvement, stated that the treatment success outcome measured in incontinence episodes was associated with a clinically meaningful improvement in disease-specific health-related quality of life for those with OAB (with urgency incontinence) [28].

Furthermore, it is hypothesized that urodynamic confirmation of treatment success secures long-term success of treatment as placebo effect can be ruled out. Results from this study are too preliminary to draw such a conclusion. Therefore, a prospective evaluation in a larger cohort is needed. As stated earlier there should also be included the special aim to justify a shorter SNM test period.

From our results, it can be concluded that ambulatory-UDS can be used to assess the test evaluation in both par-

tial or complete urinary retention and in patients with OAB. A limitation is of course the small number of patients with OAB symptoms in the total study group.

Conclusion

There is a significant correlation between the subjective, voiding diary parameters and results of ambulatory urodynamic studies in patients pre- and post SNM. Hence, an ambulatory UDS can be a useful tool in the selection of successful candidates for permanent SNM therapy. Using ambulatory-UDS to confirm success, instead of voiding diaries, could in the future justify the shortening of the test period.

Acknowledgement

The personnel of the Urology department of the Maastricht University Medical Centre are gratefully acknowledged for their contribution towards this study.

Disclosure Statement

The authors declare that they have no conflict of interest. The local Medical Ethics Committee approved the study protocol. Clinical informed consent was obtained from all patients for the additional ambulatory-UDS.

Author's contribution

J.D.: Project development, Data collection, Data analysis, Manuscript writing. K.L.J.R.: Project development, Data analysis, Manuscript editing. S.R.: Project development, Data collection, Manuscript editing. T.M.: Project development, Data collection, Manuscript editing. P.K.: Project development, Manuscript editing. G.K.: Project development, Manuscript editing.

References

- 1 Van Kerrebroeck PE, Marcelissen TA: Sacral neuromodulation for lower urinary tract dysfunction. *World J Urol* 2012;30:445–450.
- 2 Jairam R, Drossaerts J, van Koevinge G, van Kerrebroeck P: The impact of duration of complaints on successful outcome of sacral neuromodulation. *Urol Int* 2017;99:51–55.
- 3 Jonas U, Fowler CJ, Chancellor MB, et al: Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. *J Urol* 2001;165:15–19.
- 4 Everaert K, Plancke H, Lefevre F, Oosterlinck W: The urodynamic evaluation of neuromodulation in patients with voiding dysfunction. *Br j Urol* 1997;79:702–707.

- 5 DasGupta R, Fowler CJ: Urodynamic study of women in urinary retention treated with sacral neuromodulation. *J Urol* 2004;171: 1161–1164.
- 6 Weil EH, Ruiz-Cerdá JL, Eerdmans PH, Janknegt RA, Bemelmans BL, van Kerrebroeck PE: Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. *Eur Urol* 2000;37:161–171.
- 7 Hassouna MM, Siegel SW, Njeholt AA, et al: Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. *J Urol* 2000;163: 1849–1854.
- 8 Scheepens WA, van Koevinge GA, de Bie RA, Weil EH, van Kerrebroeck PE: Urodynamic results of sacral neuromodulation correlate with subjective improvement in patients with an overactive bladder. *Eur Urol* 2003;43:282–287.
- 9 van Koevinge GA, Rahnama'i MS, Berghmans BC: The additional value of ambulatory urodynamic measurements compared with conventional urodynamic measurements. *BJU Int* 2010;105:508–513.
- 10 van Waalwijk van Doorn E, Anders K, Khullar V, et al: Standardisation of ambulatory urodynamic monitoring: report of the standardisation sub-committee of the international continence society for ambulatory urodynamic studies. *Neurourol Urodyn* 2000;19: 113–125.
- 11 Comarr AE: Excretory cystometry: a more physiologic method. *J Urol* 1957;77:622–633.
- 12 van Waalwijk van Doorn ES, Remmers A, Janknegt RA: Extramural ambulatory urodynamic monitoring during natural filling and normal daily activities: evaluation of 100 patients. *J Urol* 1991;146:124–131.
- 13 Rowan D, James ED, Kramer AE, Sterling AM, Suhel PF: Urodynamic equipment: technical aspects. Produced by the international continence society working party on urodynamic equipment. *J Med Eng Technol* 1987; 11:57–64.
- 14 Abarbanel J, Marcus EL: Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. *Urology* 2007;69:436–440.
- 15 Drossaerts J, Rademakers K, van Koevinge G, Van Kerrebroeck P: The value of urodynamic tools to guide patient selection in sacral neuromodulation. *World J Urol* 2015;33: 1889–1895.
- 16 Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Ruud Bosch JL: Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. *J Urol* 2000;164:1201–1205.
- 17 Groutz A, Blaivas JG, Chaikin DC, et al: Non-invasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests. *J Urol* 2000;164(3 pt 1):698–701.
- 18 Bradley CS, Brown JS, Van Den Eeden SK, Schembri M, Ragins A, Thom DH: Urinary incontinence self-report questions: reproducibility and agreement with bladder diary. *Int Urogynecol J* 2011;22:1565–1571.
- 19 Homma Y, Yamaguchi O, Kageyama S, Nishizawa O, Yoshida M, Kawabe K: Nocturia in the adult: classification on the basis of largest voided volume and nocturnal urine production. *J Urol* 2000;163:777–781.
- 20 Okamura K, Nagata H, Nagahama K, Nojiri Y, Kanoh H, Miyazaki M: [Assessment criteria of lower urinary tract symptom severity for general practitioners]. *Nihon Hinyokika Gakkai zasshi* 2006;97:568–574.
- 21 van Venrooij GE, Eckhardt MD, Gisolf KW, Boon TA: Data from frequency-volume charts versus filling cystometric estimated capacities and prevalence of instability in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Neurourol Urodyn* 2002;21:106–111.
- 22 Blaivas JG, Marks BK, Weiss JP, Panagopoulos G, Somaroo C: Differential diagnosis of overactive bladder in men. *J Urol* 2009;182: 2814–2817.
- 23 Tincello DG, Richmond DH: The Larsen frequency/volume chart is not a substitute for cystometry in the investigation of women with urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 1998;9:391–396.
- 24 Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P: Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. *Neurourol Urodyn* 2011;30: 556–562.
- 25 Digesu GA, Gargasole C, Hendricksen C, et al: ICS teaching module: Ambulatory urodynamic monitoring. *Neurourol Urodyn* 2017; 36:364–367.
- 26 Reynolds WS, Bales GT: Re: Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. P. E. van Kerrebroeck, A. C. van Voskuilen, J. P. Heesakkers, A. A. Lycklama a Nijholt, S. Siegel, U. Jonas, C. J. Fowler, M. Fall, J. B. Gajewski, M. M. Hassouna, F. Cappellano, M. M. Elhilali, D. F. Milam, A. K. Das, H. E. Dijkema and U. van den Hombergh. *J Urol* 2007;178:2029–2034. *J Urology* 2008;179:2483–2484; author reply 2484.
- 27 Peeters K, Sahai A, De Ridder D, Van Der Aa F: Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. *BJU Int* 2014;113:789–794.
- 28 Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD: Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. *BMC Urol* 2009;9:18.